You are here: Home > Human Cell Lines > Breast Cancer Cell Lines (SUM)

Breast Cancer Cell lines

Through licensing agreements with the University of Michigan and the Karmanos Cancer Institute, Asterand provides 11 well characterized human breast cancer cell lines to assist in breast cancer research.

Ten SUM cell lines derived in Steve Ethierís lab while present at the University of Michigan are available for purchase. Each cell line, from a single patient, represents a different subtype of breast cancer. All of the currently known oncogenes with altered expression patterns in breast cancer, in various combinations, are represented and characterized in the SUM lines. These cell lines have been described in over 50 peer-reviewed publications, describing isolation and growth conditions, gene expression data through the use of Affymetrix GeneChips, and biomolecular markers, such as estrogen receptor and Her2 status. Click here to see a bibliography.

All cell lines are provided in cryovial of ~1x106 cells. All of the cell lines available from Asterand were developed in conjunction with different academic institutions. As a result of our agreements with these institutions, we offer our cell lines to academic and governmental researchers at prices lower than those available to our commercial customers. If you have any questions about this policy, please email us at advantage@asterand.com.
Sort By:
Page of 1
SUM-102PT
Our Price: $6,000.00

The SUM102 cell line was developed from a patient with minimally invasive, ER negative and PR negative human breast carcinoma. The cell line is a representative of a class of human breast cancers characterized by a high level of EGFR expression in the absence of gene amplification.

SUM-1315MO2
Our Price: $6,000.00

A cell line developed from a mouse xenograft derived by transplantation of a metastatic nodule of a patient with infiltrating ductal carcinoma.
SUM-149PT
Our Price: $6,000.00

Derived from a primary inflammatory ductal carcinoma of the breast, from a patient with locally advanced disease.
SUM-159PT
Our Price: $6,000.00

This is a triple negative breast cancer cell line.

A cell line isolated from a primary tumor of a patient with anaplastic carcinoma of the breast.
SUM-185PE
Our Price: $6,000.00

Derived from pleural effusion obtained from a patient with ductal carcinoma of the breast. Cytological examination of the effusion specimen confirmed the presence of carcinoma cells in the specimen.
SUM-190PT
Our Price: $6,000.00

Derived from a poorly differentiated inflammatory breast carcinoma. By immunohistochemistry these cancer cells were HER-2 positive, as well as ER and PR negative.
SUM-225CWN
Our Price: $6,000.00

SUM-225CWN

Breast cancer cell line derived at the Univeristy of Michigan known as SUM-225CWN

SUM-225CWN was derived from a primary human recurrent ductal carcinoma chest wall nodule. The cell line is ER-, PR-, Her2+, expresses luminal cytokeratins 8, 18 & 19 and is known to form tumors in-vivo.

Derived from a chest wall recurrence in a patient diagnosed and treated six years previously for ductal carcinoma in situ. The chest wall specimen was positive for adenocarcinoma.

DOWNLOAD INSTRUCTION BOOKLET
***Asterand Bioscience highly suggest that frozen products are shipped utilizing a cryoport to ensure that products are maintained in a frozen state throughout the shipping process. Unless cryoport shipping is selected at checkout, all frozen products will be shipped on dry ice and scheduled for estimated 2 day delivery. All international orders of frozen products will default to cryoport shipping.***

While Asterand Bioscience takes precautions with shipping and handling, we cannot control issues due to weather, customs or other unforeseen issues. These issues may prevent the package from being delivered within the appropriate time frame for any item shipped on dry ice.
SUM-229PE
Our Price: $6,000.00

This is a triple negative breast cancer cell line.
The SUM-229PE cell line was derived from pleural effusion obtained from a patient with ER negative breast cancer.
SUM-44PE
Our Price: $6,000.00

Developed from a pleural effusion from a patient with ER positive breast cancer.
SUM-52PE
Our Price: $6,000.00

Developed from a pleural effusion, from a patient with ER positive breast cancer.